Economic evaluation and end-stage renal disease: From basics to bedside
- 1 July 2000
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 36 (1) , 12-28
- https://doi.org/10.1053/ajkd.2000.8235
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Recent advances: NephrologyBMJ, 2000
- A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal diseaseAmerican Journal of Kidney Diseases, 1997
- Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patientsNephrology Dialysis Transplantation, 1996
- The Hemodialysis (HEMO) Study: Rationale for Selection of InterventionsSeminars in Dialysis, 1996
- Benefits and Costs of Recombinant Human Erythropoietin for End-Stage Renal Failure: A Review: Benefits and Costs of ErythropoietinInternational Journal of Technology Assessment in Health Care, 1993
- Survival as an index of adequacy of dialysisKidney International, 1992
- Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.BMJ, 1992
- Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.BMJ, 1990
- Comparative Cost/Benefit Analysis in Early and Late DialysisNephron, 1983
- Effect of the Hemodialysis Prescription on Patient MorbidityNew England Journal of Medicine, 1981